Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program

<p>LOS ALTOS, Calif., June 29, 2023 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today provided an update based on recent interactions with the U.S. Food and Drug Administration (FDA or Agency) concerning the Company’s New Drug Application (NDA) for lanthanum […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/unicycive-therapeutics-provides-regulatory-update-on-lanthanum-dioxycarbonate-program/">Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>